Abstract
In this study, we prepare a biocompatible and magnetic material coated with dopamine (Fe3O4/SiO2@DA) for drug delivery of doxorubicin. Doxorubicin is a commercially available drug for the treatment of several types of cancers such as metastatic breast carcinoma, blood, lungs, ovarian carcinoma, and sarcoma. Magnetic nanoparticles are synthesized by co-precipitation method and coated with dopamine. Characterization of materials is carried out by Fourier transform infrared spectroscopy, scanning electron microscopy, and energy-dispersive X-ray spectroscopy. Magnetic properties of the particles are evaluated by magnetic moment measurements. Later, this material is applied to the targeted delivery of doxorubicin. Several experimental parameters such as loading time, release time, loading temperature, release temperature, desorption pH, amount of nanomaterial, salt concentration, and effect of solvent are optimized. Loading of a drug is maximum in basic pH while acidic pH (3.3) works best for the desorption process. With increasing the amount of material, loading of drug increase. Moreover, salt (NaCl) concentration does not affect the loading process. Loading of a drug is maximum at a lower temperature (room temperature) while the release is more efficient at a higher temperature (40–45 °C). This material showed superior efficiency (drug loading, drug release, and time) as compared to previously reported similar materials. These results indicate that Fe3O4/SiO2@DA has excellent potential to carry the drug and deliver to cancerous cells which have acidic pH and higher temperature as compared to normal healthy cells.
Graphic abstract
Similar content being viewed by others
References
Judson I, Verweij J, Gelderblom H, Hartmann JT, Schöffski P, Blay JY, Kerst JM, Sufliarsky J, Whelan J, Hohenberger P (2014) Lancet Oncol 15:415
Peiris D, Spector AF, Lomax-Browne H, Azimi T, Ramesh B, Loizidou M, Welch H, Dwek MV (2017) Sci Rep 7:43006
Vig B (1971) Cancer Res 31:32
Von Hoff DD, Layard MW, Basa P, Davis HL, Von Hoff AL, Rozencweig M, Muggia FM (1979) Ann Intern Med 91:710
Gottesman MM, Fojo T, Bates SE (2002) Nat Rev Cancer 2:48
Hesketh PJ, Sanz-Altamira P (2012) Supportive Care Cancer 20:653
Hu J, Xie L, Zhao W, Sun M, Liu X, Gao W (2015) Chem Commun 51:11405
Zhang W, Guo Z, Huang D, Liu Z, Guo X, Zhong H (2011) Biomaterials 32:8555
Bagalkot V, Farokhzad OC, Langer R, Jon S (2006) Angew Chem 118:8329
Gabizon A, Catane R, Uziely B, Kaufman B, Safra T, Cohen R, Martin F, Huang A, Barenholz Y (1994) Cancer Res 54:987
Kim D, Jeong YY, Jon S (2010) ACS Nano 4:3689
Suri SS, Fenniri H, Singh B (2007) J Occupat Med Toxicol 2:16
Cole AJ, Yang VC, David AE (2011) Trends Biotechnol 29:323
Goldberg DS, Vijayalakshmi N, Swaan PW, Ghandehari H (2011) J Control Release 150:318
Dutta T, Jain NK (2007) Biochim Biophys Acta Gen Subj 1770:681
Löbenberg R, Maas J, Kreuter J (1998) J Drug Target 5:171
Gao N, Yang W, Nie H, Gong Y, Jing J, Gao L, Zhang X (2017) Biosens Bioelectron 96:300
Singh SK, Singh S, Lillard JW Jr, Singh R (2017) Int J Nanomed 12:6205
Wang Y, Luo Y, Zhao Q, Wang Z, Xu Z, Jia X (2016) ACS Appl Mater Interfaces 8:19899
Lv R, Yang P, He F, Gai S, Yang G, Dai Y, Hou Z, Lin J (2015) Biomaterials 63:115
Lv R, Yang P, He F, Gai S, Yang G, Lin J (2015) Chem Mater 27:483
Torchilin VP (2014) Nat Rev Drug Discov 13:813
Xu HL, Mao KL, Huang YP, Yang JJ, Xu J, Chen PP, Fan ZL, Zou S, Gao ZZ, Yin JY, Xiao J, Lu CT, Zhang BL, Zhao YZ (2016) Nanoscale 8:14222
Lee N, Yoo D, Ling D, Cho MH, Hyeon T, Cheon J (2015) Chem Rev 115:10637
Chen RJ, Chen PC, Prasannan A, Vinayagam J, Huang CC, Chou PY, Weng CC, Tsai HC, Lin SY (2016) Mater Sci Eng C 63:678
Stocke NA, Meenach SA, Arnold SM, Mansour HM, Hilt JZ (2015) Int J Pharm 479:320
Griffete N, Fresnais J, Espinosa A, Wilhelm C, Bée A, Ménager C (2015) Nanoscale 7:18891
Xing R, Bhirde AA, Wang S, Sun X, Liu G, Hou Y, Chen X (2013) Nano Res 6:1
Tian B, Liu S, Wu S, Lu W, Wang D, Jin L, Hu B, Li K, Wang Z, Quan Z (2017) Colloids Surf B 154:287
Miranda MS, Rodrigues MT, Domingues RM, Costa RR, Paz E, Rodríguez-Abreu C, Freitas P, Almeida BG, Carvalho MA, Gonçalves C (2018) Adv Healthc Mater 10:1800124
Quan Q, Xie J, Gao H, Yang M, Zhang F, Liu G, Lin X, Wang A, Eden HS, Lee S, Zhang G, Chen X (2011) Mol Pharm 8:1669
Idris MI, Zaloga J, Detsch R, Roether JA, Unterweger H, Alexiou C, Boccaccini AR (2018) Sci Rep 8:7286
Kang T, Li F, Baik S, Shao W, Ling D, Hyeon T (2017) Biomaterials 136:98
Wu M, Zhang D, Zeng Y, Wu L, Liu X, Liu J (2015) Nanotechnology 26:115102
Huang L, Ao L, Wang W, Hu D, Sheng Z, Su W (2015) Chem Commun 51:3923
Mohyuddin A, Hussain D, Najam-ul-Haq M (2017) RSC Adv 7:9476
Mrówczyński R, Jurga-Stopa J, Markiewicz R, Coy EL, Jurga S, Woźniak A (2016) RSC Adv 6:5936
Acknowledgements
The present work was financially supported by Office of Research Innovation and Commercialization (ORIC), Bahuddin Zakariya University Multan, Pakistan under Grant no. DR & EL/D-740 and Institute of Chemical Sciences, Bahuddin Zakariya University Multan, Pakistan. Dr. Miss. Saadat Majeed is very thankful to Prof. Dr. Guobao Xu CIAC, CAS Changchun, China for his mentorship and supervision during her PhD studies, and on tailoring her capabilities to run an independent research group.
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Naqvi, S.T.R., Rasheed, T., Hussain, D. et al. Development of molecularly imprinted magnetic iron oxide nanoparticles for doxorubicin drug delivery. Monatsh Chem 151, 1049–1057 (2020). https://doi.org/10.1007/s00706-020-02644-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00706-020-02644-z